These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22911710)

  • 1. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
    Wang E; Zhao Y; Monaco A; Uccellini L; Kirkwood JM; Spyropoulou-Vlachou M; Panelli MC; Marincola FM; Gogas H
    PLoS One; 2012; 7(7):e40805. PubMed ID: 22911710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.
    Tarhini AA; Lin Y; Zahoor H; Shuai Y; Butterfield LH; Ringquist S; Gogas H; Sander C; Lee S; Agarwala SS; Kirwood JM
    PLoS One; 2015; 10(7):e0132745. PubMed ID: 26192408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
    Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
    Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
    Gogas H; Kirkwood JM; Falk CS; Dafni U; Sondak VK; Tsoutsos D; Stratigos A; Markopoulos C; Pectasides D; Spyropoulou-Vlachou M
    Cancer; 2010 Sep; 116(18):4326-33. PubMed ID: 20549830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
    Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
    Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
    Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
    [No Abstract]   [Full Text] [Related]  

  • 7. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
    Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
    J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
    Gogas H; Dafni U; Koon H; Spyropoulou-Vlachou M; Metaxas Y; Buchbinder E; Pectasides E; Tsoutsos D; Polyzos A; Stratigos A; Markopoulos C; Panagiotou P; Fountzilas G; Castana O; Skarlos P; Atkins MB; Kirkwood JM
    J Transl Med; 2010 Nov; 8():108. PubMed ID: 21044351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
    Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
    Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
    Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
    Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
    J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
    Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
    Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
    Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
    Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
    Wagner SN; Rebmann V; Willers CP; Grosse-Wilde H; Goos M
    Lancet; 2000 Jul; 356(9225):220-1. PubMed ID: 10963203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
    Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
    J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.